Single‐cell RNA‐seq analysis reveals the platinum resistance gene COX7B and the surrogate marker CD63

  title={Single‐cell RNA‐seq analysis reveals the platinum resistance gene COX7B and the surrogate marker CD63},
  author={Nobuyuki Tanaka and Shintaro Katayama and Aparna Reddy and Kaneyasu Nishimura and Naoya Niwa and Hiroshi Hongo and Koichiro Ogihara* and Takeo Kosaka and Ryuichi Mizuno and Eiji Kikuchi and Shuji Mikami and Ayako Miyakawa and Ernest Arenas and Juha Kere and Mototsugu Oya and Per Uhl{\'e}n},
  journal={Cancer Medicine},
  pages={6193 - 6204}
Cancers acquire resistance to systemic treatment with platinum‐based chemotherapy (eg, cisplatin [CDDP]) as a result of a dynamic intratumoral heterogeneity (ITH) and clonal repopulation. However, little is known about the influence of chemotherapy on ITH at the single‐cell level. Here, mapping the transcriptome of cancers treated with CDDP by scRNA‐seq, we uncovered a novel gene, COX7B, associated with platinum‐resistance, and surrogate marker, CD63. Knockdown of COX7B in cancer cells… 

TNFAIP2 expression induces epithelial-to-mesenchymal transition and confers platinum resistance in urothelial cancer cells

The present results suggest a relationship between TNFAIP2 and EMT in cancers under the control of CDDP, in which MTDH expression levels in cancer cells are vital for promoting TN FAIP2-derived EMT acquisition.

Single-Cell Sequencing in Genitourinary Malignancies.

The ability of SCS to resolve intratumor heterogeneity and better define the genomic landscape of tumors and CTCs will be fundamental in the new era of precision-based care.

Single-cell sequencing technologies in bladder cancer research: Applications and challenges

This review summarises and discusses how single-cell sequencing technologies have been applied in bladder cancer research, to advance collective knowledge on the heterogeneity of bladder tumor cells, as well as to provide new insights into the complex ecosystem of the tumor microenvironment.

Single-Cell Gene Network Analysis and Transcriptional Landscape of MYCN-Amplified Neuroblastoma Cell Lines

A transcriptome-wide quantitative measurement of gene expression and transcriptional network activity in BE2C and Kelly cell lines at an unprecedented single-cell resolution is provided, and it is shown that MYCN is not constantly active or expressed within Kelly andBE2C cells, independently of cell cycle phase.

Single-cell sequencing and its applications in bladder cancer

The advances in single-cell technologies are reviewed and their applications in cancer research and clinical practice are discussed, with a specific focus on bladder cancer.

Tumor heterogeneity in muscle-invasive bladder cancer

Insight is provided into the clinical significance of the molecular mechanisms underlying heterogeneity, focusing on inter- and intra-tumor heterogeneity, with special emphasis on molecular classification and methods used to analyze the complex patterns involved.

Single Cell Gene Co-Expression Network Reveals FECH/CROT Signature as a Prognostic Marker

The heterogeneous function of “generation of precursor metabolites and energy” upon androgen stimulation from the perspective of single cells is revealed, and survival analysis indicates that FECH/CROT signature can predict PCa recurrence.

Identification of a Nuclear Mitochondrial-Related Multi-Genes Signature to Predict the Prognosis of Bladder Cancer

Not only could the signature and prognostic nomogram predict the prognosis of BC, but it also had potential therapeutic guidance and outperformed each involved MTRG.

Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications

The recent progress in overcoming cancer drug resistance is summarized in three novel aspects: mRNA modification, which includes alternative splicing, A-to-I modification and mRNA methylation, and posttranslational modification on molecules, which encompasses drug inactivation/efflux, drug target modifications, DNA damage repair, cell death resistance, EMT, and metastasis.

Applications of single-cell sequencing in cancer research: progress and perspectives

The prospects of single-cell sequencing in facilitating diagnosis, targeted therapy and prognostic prediction among a spectrum of tumors are bright and advances in single- cell sequencing will undoubtedly improve the understanding of the biological characteristics of tumors and highlight potential precise therapeutic targets for patients.



Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell‐like profile

It is demonstrated that cisplatin‐induced transition from epithelial to mesenchymal morphology in residual cancer cells correlated with reduced E‐cadherin, and increased N‐c cadherin and vimentin expression, and that targeting ERK2 in the presence of cisPlatin may reduce the burden of residual tumor, the ultimate cause of recurrence in ovarian cancer patients.

RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance

Analysis of circulating tumor cells from prostate cancer patients reveals a mechanism that contributes to treatment failure, and a non-invasive method to spot resistance by sequencing RNA transcripts in single circulating tumor Cells (CTCs) is developed.

Acquired platinum resistance involves epithelial to mesenchymal transition through ubiquitin ligase FBXO32 dysregulation.

The association between FBXO32 expression and EMT was further validated using clinical samples and suggest the importance of the association between EMT and ubiquitin-proteasome regulation when tumors develop acquired platinum resistance.

Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors.

The data suggest that intrinsic and acquired chemoresistant phenotypes of post-CT tumors may be attributed to the combined action of different factors implicated in mechanisms of chemoresistance, tumor invasion/progression and control of cell proliferation.

Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors.

BRCA2 reversion mutations in patients with prostate cancer with metastatic disease who developed resistance to talazoparib and olaparib are identified and it is shown that PARPi resistance is highly multiclonal and that cfDNA allows monitoring for PAR Pi resistance.

Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance

It is shown that human melanoma cells can display profound transcriptional variability at the single-cell level that predicts which cells will ultimately resist drug treatment, and this work reveals the multistage nature of the acquisition of drug resistance and provides a framework for understanding resistance dynamics in single cells.

Single-cell analyses of transcriptional heterogeneity during drug tolerance transition in cancer cells by RNA sequencing

Single-cell analyses reveal the dynamics of the stress response in terms of cell-specific RNA variants driving heterogeneity, the survival of a minority population through generation of specific RNA variants, and the efficient reconversion of stress-tolerant cells back to normalcy.

Enhanced expression of DNA polymerase eta contributes to cisplatin resistance of ovarian cancer stem cells

An elevated expression of DNA polymerase η (Pol η) in ovarian CSCs isolated from both ovarian cancer cell lines and primary tumors is reported, indicating that C SCs may have intrinsically enhanced translesion DNA synthesis (TLS).

Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer.

No gene expression profile predicting the response of primary breast carcinomas to AC- or AD-based neoadjuvant chemotherapy could be detected in this interim analysis.

Acquired platinum resistance enhances tumour angiogenesis through angiotensin II type 1 receptor in bladder cancer

A new molecular mechanism for upregulated AT1R signalling through increased ROS when tumours progressed after the CDDP-based regimens is indicated, and light is shed on the importance of At1R blockade for platinum-resistant bladder cancers.